Ki | |||
---|---|---|---|
WT | WT S3.36A | Ratio | |
nM | |||
5-HT | 267 ± 86 | 7,460 ± 1,112 | 27.9 |
N-Me-5-HT | 197 ± 19 | 1,589 ± 145 | 8.1 |
N,N-dMe-5-HT | 162 ± 14 | 645 ± 88 | 4 |
5-MeOT | 183 ± 16 | 3,631 ± 295 | 19.8 |
N-Me-5-MeOT | 137 ± 35 | 748 ± 126 | 5.5 |
N,N-dMe-5-MeOT | 121 ± 17 | 554 ± 90 | 4.6 |
4-HT | 673 ± 106 | 6,085 ± 745 | 9 |
N,N-dMe-4-HT | 95 ± 13 | 360 ± 76 | 3.8 |
TRYP | 960 ± 133 | 11,250 ± 1,451 | 11.7 |
N-Me-TRYP | 509 ± 56 | 2560 ± 452 | 5 |
N,N-dMe-TRYP | 366 ± 41 | 982 ± 130 | 2.7 |
LSD | 0.38 ± 0.05 | 0.54 ± 0.13 | 1.4 |
Lisuride | 0.59 ± 0.01 | 0.58 ± 0.03 | 1 |
BOL | 0.22 ± 0.01 | 0.38 ± 0.01 | 1.7 |
Ergonovine | 0.76 ± 0.02 | 1.7 ± 0.2 | 2.2 |
Methysergide | 6.7 ± 0.3 | 11.3 ± 0.5 | 1.7 |
Mesulergine | 23 ± 2 | 38 ± 2 | 1.7 |
Values for K i were determined from [3H]ketanserin competition binding curves. Ratio =K i for S3.36A/K i for WT. Data are mean ± S.E. from 3–14 experiments.